Royal Philips and IBA, a specialist in proton therapy solutions, have announced a global collaboration to further diagnostic solutions for the treatment of cancer. The agreement covers sales, marketing, and research and development of oncology treatment and imaging solutions to provide more personalized cancer care.
“Proton therapy is one of the most exciting technological advancements in the oncology field,” said Gene Saragnese, executive vice president and CEO, Imaging Systems, Philips. “We look forward to collaborating with IBA to enhance access to best-in-class technology for both proton centers and molecular imaging centers, as well as to accelerate the development of our informed therapy guidance vision in ways that can change the future of care, and improve the quality of life for patients.”
According to the announcement, the agreement will allow each company to leverage the other’s specialty. Philips will offer IBA proton therapy solutions within its imaging equipment in select markets, while IBA will benefit from Philips imaging solutions offered to oncology care centers. The companies will also collaborate on a combined offering for molecular imaging centers that integrates IBA’s strength in PET radioisotope production centers with Philips’ imaging and diagnostic expertise.
Improved cancer care through the use of proton therapy has the potential to reduce the short- and long-term side effects of cancer treatment while improving the patient’s quality of life throughout the process. The technique could also reduce costs for the healthcare system.